We are live on ! Find out more
ASMB icon

Assembly Biosciences

103 hedge funds and large institutions have $435M invested in Assembly Biosciences in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

374% more call options, than puts

Call options by funds: $3.95M | Put options by funds: $833K

33% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 30

0.22% more ownership

Funds ownership: 6.99%7.21% (+0.22%)

3% less funds holding

Funds holding: 106103 (-3)

10% less capital invested

Capital invested by funds: $483M → $435M (-$47.5M)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
103
Holders Change
-3
Holders Change %
-2.83%
% of All Funds
2.23%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
40
Reduced
30
Closed
14
Calls
$3.95M
Puts
$833K
Net Calls
+$3.11M
Net Calls Change
+$3.21M
Name Holding Trade Value Shares
Change
Change in
Stake
Jennison Associates
1
Jennison Associates
New York
$48.7M -$65.6K -259 -0.1%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$44.9M -$798K -3,153 -2%
BlackRock
3
BlackRock
New York
$34.3M -$3.58M -14,127 -9%
EC
4
EcoR1 Capital
California
$22.7M -$26.4M -104,271 -52%
AC
5
Armistice Capital
New York
$22.2M +$21.7M +85,667 +1,028%
Vanguard Group
6
Vanguard Group
Pennsylvania
$21.3M +$5.1M +20,160 +29%
O
7
OrbiMed
New York
$19.6M
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$18.8M -$29.9K -118 -0.1%
ACA
9
Avoro Capital Advisors
New York
$17.7M -$2.11M -8,333 -10%
State Street
10
State Street
Massachusetts
$16.1M +$8.03M +31,705 +87%
ACP
11
Acuta Capital Partners
California
$15M +$886K +3,500 +6%
SAM
12
Sectoral Asset Management
Quebec, Canada
$14.1M +$11.8M +46,533 +355%
Victory Capital Management
13
Victory Capital Management
Texas
$11.1M +$665K +2,625 +6%
EA
14
Emerald Advisers
Pennsylvania
$9.22M +$1.67M +6,587 +20%
RSCM
15
Rock Springs Capital Management
Maryland
$8.86M
Fidelity Investments
16
Fidelity Investments
Massachusetts
$8.78M +$56.5K +223 +0.6%
EMFAT
17
Emerald Mutual Fund Advisers Trust
Pennsylvania
$8.23M +$1.04M +4,102 +13%
PM
18
Prosight Management
Texas
$6.19M +$812K +3,206 +14%
Northern Trust
19
Northern Trust
Illinois
$5.73M +$116K +458 +2%
Axa
20
Axa
France
$5.04M +$1.73M +6,818 +47%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$5.03M +$579K +2,285 +12%
Citadel Advisors
22
Citadel Advisors
Florida
$4.36M +$2.62M +10,338 +128%
Marshall Wace
23
Marshall Wace
United Kingdom
$4.33M -$2.57M -10,162 -36%
JP Morgan Chase
24
JP Morgan Chase
New York
$4M +$2.5M +9,883 +140%
VFA
25
Valeo Financial Advisors
Indiana
$3.96M +$21K +83 +0.5%

ASMB Hedge Fund Activity: Q1 2019 in Review

103 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2019, worth a combined $435M — down 9.8% from $483M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ASMB and 11 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 40 added.

The largest buyer was Armistice Capital, adding an estimated $21.7M. The largest seller was EcoR1 Capital, cutting an estimated $26.4M.

  • 103 institutional investors held Assembly Biosciences (ASMB) as of Q1 2019, down from 106 in Q4 2018.
  • Funds reported $435M of Assembly Biosciences stock for Q1 2019, down 9.8% quarter-over-quarter.
  • 11 funds opened new Assembly Biosciences positions in Q1 2019 and 14 closed out, a net change of -3 holders.
  • The largest Assembly Biosciences buyer in Q1 2019 was Armistice Capital, an estimated $21.7M added.
  • The largest Assembly Biosciences seller in Q1 2019 was EcoR1 Capital, an estimated $26.4M sold.

Based on aggregated 13F filings for Q1 2019.